Change in number of shares and votes in Episurf Medical
Episurf Medical AB (NASDAQ: EPIS B) has, pursuant to previously announced information, carried out a rights issue of units consisting of shares of series B and warrants of series TO13 B. The rights issue has resulted in a change in the number of shares and votes in the company. Through the rights issue, the number of shares has increased by 375,662,430 shares of series B and the number of votes has increased by 375,662,430.
Furthermore, the company has, pursuant to previously announced information, carried out a set-off issue of units consisting of shares of series B and warrants of series TO13 B directed to certain guarantors in the rights issue. The set-off issue has resulted in a change in the number of shares and votes in the company. Through the set-off issue, the number of shares has increased by 8,749,965 shares of series B and the number of votes has increased by 8,749,965.
As a consequence of the above-mentioned changes, the total number of shares amounts to 651,477,842, of which 473,357 are shares of series A and 651,004,485 are shares of series B, and the total number of votes amounts to 652,424,556.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CEST on 28 June 2024.